BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34583800)

  • 1. Outcomes of clinical decision support for outpatient management of
    Wu T; Davis SL; Church B; Alangaden GJ; Kenney RM
    Infect Control Hosp Epidemiol; 2022 Oct; 43(10):1345-1348. PubMed ID: 34583800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
    Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
    Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
    Okumura H; Ueyama M; Shoji S; English M
    J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
    Okumura H; Fukushima A; Taieb V; Shoji S; English M
    J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.
    Novosad SA; Mu Y; Winston LG; Johnston H; Basiliere E; Olson DM; Farley MM; Revis A; Wilson L; Perlmutter R; Holzbauer SM; Whitten T; Phipps EC; Dumyati GK; Beldavs ZG; Ocampo VLS; Davis CM; Kainer M; Gerding DN; Guh AY
    J Gen Intern Med; 2020 Feb; 35(2):412-419. PubMed ID: 31768906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
    Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
    Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is shorter also better in the treatment of Clostridioides difficile infection?
    Duricek M; Halmova K; Krutova M; Sykorova B; Benes J
    J Antimicrob Chemother; 2024 Jun; 79(6):1413-1417. PubMed ID: 38661207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
    Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
    JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clostridioides difficile - New Insights and Therapy Recommendations].
    Schönherr S; Jung L; Lübbert C
    Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
    Krutova M; Wilcox M; Kuijper E
    Int J Infect Dis; 2022 Nov; 124():118-123. PubMed ID: 36155825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutics for
    Khanna S; Voth E
    Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
    Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
    J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.